Merck KGaA, Caris enter $1.4B ADC deal

05 Apr 2024

·www.pharmamanufacturing.com

License out/inADC

Merck KGaA has entered into a partnership with Caris Life Sciences, a company specializing in artificial intelligence and precision medicine, to accelerate the development of antibody-drug conjugates (ADCs) for cancer treatment.

Per the deal, Caris will receive an upfront payment and research funding from Merck KGaA. The deal includes potential discovery, development, regulatory, and sales milestone payments to Caris, which may total up to $1.4 billion, in addition to tiered royalties.

In return, Merck KGaA obtains an exclusive global license to develop, manufacture and commercialize ADC therapeutics for targets identified through this collaboration.

The initiative utilizes Caris Discovery, Caris' therapeutic research arm, employing its proprietary ADAPT Biotargeting platform, a patient tissue repository, AI and machine learning to discover novel targets for ADCs.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Merck KGaA

Caris Life Sciences, LLC

ADC Therapeutics SA

Indications

Neoplasms

Targets

Drugs

Hot reports

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Global Drug R&D Express (Jan 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.